Literature DB >> 10993510

Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography.

G Aymard1, M Legrand, N Trichereau, B Diquet.   

Abstract

A new high-performance liquid chromatography (HPLC) with UV detection assay was developed for the simultaneous determination of protease inhibitors (PIs), nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs) using a single 1-ml plasma samples. A solid-liquid extraction procedure without internal standard was coupled with two separate reversed-phase HPLC systems; one for the determination of amprenavir, efavirenz, indinavir, nelfinavir, ritonavir, saquinavir (run time=32 min) and one for the determination of abacavir, didanosine, lamivudine, stavudine, nevirapine, zidovudine (run time=40 min). The first requires a mobile phase containing sodium phosphate buffer+ion pair-acetonitrile (50:50, v/v) through a C18 Symmetry column (250x4.6 mm I.D., 5 microm particle size), using variable wavelengths (241, 254 and 261 nm). The second system requires three mobile phases (potassium phosphate buffer+ion pair-acetonitrile) for different elution through a C18 Symmetry Shield column (250x4.6 mm I.D., 5 microm), using a single wavelength (260 nm). Peak-areas are linear; correlation coefficients are better than 0.998 for all compounds, with both inter- and intra-day relative standard deviations lower than 12%. Extraction recoveries are higher than 93% for PIs and NNRTIs and higher than 70% for NRTIs. The method is specific and sensitive and was used to determine trough and peak levels of antiretroviral drugs in HIV infected patients under various combinations of RTIs and PIs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993510     DOI: 10.1016/s0378-4347(00)00225-5

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  14 in total

1.  Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report.

Authors:  Gaëlle Hardy; Françoise Stanke-Labesque; Claudine Contamin; Françoise Serre-Debeauvais; François Bayle; Philippe Zaoui; Germain Bessard
Journal:  Eur J Clin Pharmacol       Date:  2004-09-15       Impact factor: 2.953

2.  Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

Authors:  X Panhard; C Goujard; M Legrand; A M Taburet; B Diquet; F Mentré
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

3.  Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.

Authors:  D González de Requena; S Bonora; S Garazzino; M Sciandra; A D'Avolio; R Raiteri; R Marrone; M Boffito; F G De Rosa; A Sinicco; G Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Authors:  Cécile Goujard; Mayeule Legrand; Xavière Panhard; Bertrand Diquet; Xavier Duval; Gilles Peytavin; Isabelle Vincent; Christine Katlama; Catherine Leport; Bénédicte Bonnet; Dominique Salmon-Céron; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.

Authors:  Marc Wirden; Anne Simon; Luminita Schneider; Roland Tubiana; Luc Paris; Anne Genevieve Marcelin; Constance Delaugerre; Mayeule Legrand; Serge Herson; Gilles Peytavin; Christine Katlama; Vincent Calvez
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

7.  Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

Authors:  Stéphane Mouly; Nathalie Rizzo-Padoin; Guy Simoneau; Céline Verstuyft; Guy Aymard; Cécile Salvat; Isabelle Mahé; Jean-François Bergmann
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

8.  Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.

Authors:  Xavière Panhard; Mayeule Legrand; Anne-Marie Taburet; Bertrand Diquet; Cécile Goujard; France Mentré
Journal:  Eur J Clin Pharmacol       Date:  2007-08-11       Impact factor: 2.953

9.  A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.

Authors:  Praveen Srivastava; Ganesh S Moorthy; Robert Gross; Jeffrey S Barrett
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

10.  Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: a 5-year study.

Authors:  María Jesús Hernández Arroyo; Salvador Enrique Cabrera Figueroa; Rosa Sepúlveda Correa; María de la Paz Valverde Merino; Alicia Iglesias Gómez; Alfonso Domínguez-Gil Hurlé
Journal:  Patient Prefer Adherence       Date:  2013-08-01       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.